Evidence map›Paper›PMID 36145704›Full record

ReviewPharmaceutics2022

Acyldepsipeptide Analogues: A Future Generation Antibiotics for Tuberculosis Treatment.

Sinazo Z Z Cobongela, Maya M Makatini, Phumlane S Mdluli, Nicole R S Sibuyi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Antibiotic Resistance toAntibiotics (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sinazo Z Z CobongelaNanotechnology Innovation Centre (NIC), Health Platform, Advanced Materials Division, Mintek, Randburg 2194, South Africa.
Maya M MakatiniMolecular Sciences Institute, School of Chemistry, University of the Witwatersrand, Johannesburg 2050, South Africa.
Phumlane S MdluliNanotechnology Innovation Centre (NIC), Health Platform, Advanced Materials Division, Mintek, Randburg 2194, South Africa.ORCID 0000-0002-1554-783X
Nicole R S SibuyiNanotechnology Innovation Centre (NIC), Health Platform, Advanced Materials Division, Mintek, Randburg 2194, South Africa.ORCID 0000-0001-7175-5388
Mintek · ZADurban University of Technology · ZAUniversity of the Witwatersrand · ZA

Funding

Mintek Science Vote ADR 42304
6 · The paper itself

Abstract

Acyldepsipeptides (ADEPs) are a new class of emerging antimicrobial peptides (AMPs), which are currently explored for treatment of pathogenic infections, including tuberculosis (TB). These cyclic hydrophobic peptides have a unique bacterial target to the conventional anti-TB drugs, and present a therapeutic window to overcome

Indexed as

acyldepsipeptidesantibioticsantimicrobialantimicrobial peptidescaseinolytic proteasemulti-drug resistance bacteriaMycobacterium tuberculosisnanomaterialsproteolytic coretuberculosis

Identifiers

PMID36145704
PMCPMC9502522
OpenAlexW4296282151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.